Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

about

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

Item

http://www.wikidata.org/entity/Q55153984

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

@en

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

@nl

type

Item

label

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

@en

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

@nl

prefLabel

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

@en

Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

@nl

P1476

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

@en

P2093

Dawn Lavery

http://www.w3.org/2001/XMLSchema#string

Marc Handford

http://www.w3.org/2001/XMLSchema#string

Tessa Hanley

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review

Biologic therapy and pregnancy. A systematic literature review

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

P304

41-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PTT.S68869

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zenas Z N Yiu

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29387593

http://www.w3.org/2001/XMLSchema#string

P932

5683127

http://www.w3.org/2001/XMLSchema#string